Compare Cintas Corporation (CTAS) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Tenet Healthcare Corporation — how do they compare? Cintas Corporation trades at $202.32 (market cap $79.86B), while Tenet Healthcare Corporation trades at $262.63 (market cap $20.98B). The key difference: Cintas Corporation is far larger — about 3.8× Tenet Healthcare Corporation's market cap, and Cintas Corporation pays a 1.03% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and Tenet Healthcare Corporation for 15 Days on average.
| CTAS | THC | |
|---|---|---|
Market Cap | $79.86B | $20.98B |
Volume | 1,323,583 | 428,008 |
Sector | Industrials | Health |
52-Week High | $216.53 | $280.77 |
52-Week Low | $163.55 | $161.37 |
Typical Hold Time | 124 Days | 15 Days |
Enterprise Value | $82.33B | $32.06B |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $201.87, up 2.37% today, reflecting strong momentum after Q1 2027 earnings beat. The stock shows bullish technical signals with support near $195 and resistance at $200. Fundamentals are robust with revenue growth to $10.34B in 2025, net margin of 17.82%, and rising profitability. Recent news highlights raised guidance and record quarterly revenue exceeding $3B, signaling operational strength.
Outlook remains positive driven by organic growth and margin expansion, but high valuation multiples (P/E 39.67) pose a risk if growth slows. Analyst consensus is Moderate Buy with a $234.60 price target, implying 16% upside. Key risks include economic sensitivity and competitive pressures in uniform services.
Tenet Healthcare (THC) trades at $261.07, up 0.48% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 82.83% gross margins and consistent earnings beats, while trading at attractive valuations including a 10.07 P/E ratio. Recent news highlights upcoming Q3 2026 earnings on October 29th and positive coverage of the company's growth prospects despite surgical volume challenges.
THC presents a compelling investment case with strong analyst support (81% buy ratings) and a $283.36 consensus target offering 8.5% upside. The healthcare provider shows improving profitability with net margins expected to reach 9.89% in 2026. Key risks include capital allocation sustainability and potential volatility around upcoming earnings, but the combination of value pricing and growth momentum supports a positive outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
